



Japan

Email: hayashi@otsuka.jp

Received 19 December 2019; revised 22 December 2019;

accepted 23 December 2019.

Exploring the links between specific depression symptoms and brain structure: A network study

doi:10.1111/pcn.12969

Various patterns of structural brain abnormalities have been associated with depression, yet sensitive, specific and clinically predictive brain correlates have proven to be difficult to characterize.¹ The currently best available empirical evidence on neuroanatomical differences between patients with major depression (MDD) and healthy controls are two meta-analyses of approximately 10 000 individuals.^{2,3} These reports show widespread alterations in cortical regions and in hippocampal volume, but no associations between depression severity and brain structure. Inconsistencies in the neuroimaging literature may be explained by the fact that depression is highly heterogeneous, featuring over 50 symptoms,⁴ where

symptom constellations may reflect different phenomena with distinct underlying biological causes.¹

Understanding the neural substrates of specific symptoms may provide important information about mechanisms underlying depression vulnerability. A growing body of research under the umbrella term ‘network approach’ has recently received considerable attention⁵; the approach understands and aims to model mental disorders as systems of causally interacting symptoms. So far, network studies have been based on symptoms and environmental factors, ignoring relevant neurobiological factors.⁶ Here, we address this knowledge gap by modeling a joint network of depression-related brain structures and individual depression symptoms, using 21 symptoms and five regional brain measures. The sample is a mixed group of individuals that previously have been treated for one or more major depressive episodes (MDE) and never depressed individuals, with the goal to model a continuum of depression severity.

Depression symptoms were measured using the Beck Depression Inventory (BDI-II). MRI images were obtained from a 3T Philips scanner. Whole-brain volumetric segmentation and cortical surface reconstruction of MRI images was performed with FreeSurfer 5.3 (<https://surfer.nmr.mgh.harvard.edu/>). Five regional brain measures were selected based on the MDD case-control differences showing the largest bilateral effects in the studies from the ENIGMA MDD working group^{2,3}: hippocampal volume and cortical thickness in four regions - medial orbitofrontal cortex (mOFC), fusiform gyrus, insula and cingulate (weighted average of rostral anterior cingulate, caudal anterior cingulate and posterior cingulate). Brain structure measures were averaged across the left and right hemisphere for each participant, and z-residuals of hippocampal volume (controlling for sex and estimated intracranial volume) were calculated for further analyses. A Gaussian graphical model of the 26 variables were




Fig. 1 (a) Depression symptom network including five brain areas. Blue lines represent positive associations, red lines negative associations, and the thickness and brightness of an edge indicate the association strength. AGIT, agitation; ANHED, loss of pleasure; APPET, changes in appetite; CINGULATE, rostral-, medial-, and anterior cingulate cortex; CONC, concentration difficulty; CRITIC, self-criticism; CRY, crying; DISL, self-dislike; ENER, loss of energy; FAIL, past failure; FATIG, tiredness or fatigue; FUSIFORM, fusiform gyrus; GUILT, guilty feelings; HIPPOCAMP, hippocampus; INDECISIVE, indecisiveness; INSULA, insula; INTER, loss of interest; IRRIT, irritability; mOFC, medial orbitofrontal cortex; PESS, pessimism; PUNISH, punishment feelings; SAD, sadness; SEX, loss of interest in sex; SLEEP, changes in sleep pattern; SUIC, suicidal thoughts or wishes; WORTH, worthlessness. (b) Sparse partial correlations between brain structure measures, and between brain structure measures and depressive symptoms in the network model.

computed using the R packages qgraph and bootnet, and the graphical LASSO (least absolute shrinkage and selection operator) was used for regularization (see Appendix S1 for details on MRI acquisition, MRI processing and network analysis).

This sample was drawn from two related clinical trials and a case-control research study conducted at the Department of Psychology, University of Oslo. Informed consent was obtained from all participants before enrolment and their anonymity was preserved. The sample consists of 268 adult participants, 191 with at least one MDE [M age = 39.4 (SD = 13.2), 132 females, M education level (ISCED) level 6.0 (SD = 0.9), M BDI-II score 14.7 (SD = 10.4)] and 77 never depressed individuals [M age = 41.9 (SD = 12.9), M education level 5.7 (SD = 1.5), M BDI-II score 1.7 (SD = 2.9), 50 females]. BDI-II sum score range was 0–49. A total of 172 subjects had experienced two or more MDE's. Sixty-one participants were currently using antidepressant medication.

The symptom-brain network is depicted in Figure 1a,b. All brain structures were positively inter-connected, with regularized partial correlations up to 0.40. Hippocampus was associated with *changes in appetite sadness, loss of interest and irritability*. Insula was associated with *loss of interest in sex and sadness*. Cingulate had associations with *sadness, crying and worthlessness*. Fusiform gyrus had associations with *crying and irritability* (see stability and centrality indices, Figures S1 and S2).

Here we establish the first link between individual depression symptoms and neuroanatomy using network analysis. Our results broadly align with prior literature showing that depression symptoms differentially relate to important outcomes such as impairment and risk factors, and demonstrate the importance of studying specific features of depression over one heterogeneous category.^{5,6} The associations between symptoms and brain structure may reflect the heterogeneous nature of the disorder, and may offer important cues about underlying neural mechanisms in MDD. The results await replication in larger samples and other patient groups. In this study depression history was assessed retrospectively and previous MDE was classified independent of type of treatment, combination treatment, treatment response or time since the last episode. We hope the reported results can pave the way for future studies integrating neurobiological measures in network analyses, which represent a step toward validation of biomarkers.

Acknowledgments

We thank the Department of Psychiatry, Diakonhjemmet Hospital for help and support with recruiting patients, and the Intervention Center, OUS for radiological assistance in MRI protocols, data acquisitions and screening for unexpected neuropathological findings. We thank Tor Endestad for establishing the infrastructure for MRI research at the Department of Psychology, University of Oslo. We want to thank our MRI research assistant Dani Beck. We also thank our external recruitment sites; Unicare, Coperiosenteret AS, Torgny Syrstad, MD, Synergi Helse AS and Lovisenberg Hospital.

Disclosure statement

The project is supported by the South-Eastern Norway Regional Health Authority, grant number: 2015052 (to NIL), Research Council of Norway, grant number: 229135 (to NIL) and Department of Psychology, University of Oslo. Clin.gov ID for the two clinical trials: NCT0265862 and NCT02931487. CKT is funded by the Research Council of Norway, grant numbers: 223273; 288083; 230345 and the South-Eastern Norway Regional Health Authority, grant number: 2019069. NIL has received consultancy fees and travel expenses from Lundbeck. EH, BK, EF, LM CKT and RJ reports no biomedical financial interests or potential conflicts of interest.

References

- Insel TR, Landis SC. Twenty-five years of progress: The view from NIMH and NINDS. *Neuron* 2013; **80**: 561–567.
- Schmaal L, Veltman DJ, van Erp TG *et al*. Subcortical brain alterations in major depressive disorder: Findings from the ENIGMA Major Depressive Disorder working group. *Mol. Psychiatry* 2016; **21**: 806.
- Schmaal L, Hibar D, Sämann P *et al*. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts

worldwide in the ENIGMA Major Depressive Disorder Working Group. *Mol. Psychiatry* 2017; **22**: 900.

- Fried EI. The 52 symptoms of major depression: Lack of content overlap among seven common depression scales. *J. Affect. Disord.* 2017; **208**: 191–197.
- Borsboom D. A network theory of mental disorders. *World Psychiatry* 2017; **16**: 5–13.
- Fried EI, Cramer AOJ. Moving forward: Challenges and directions for psychopathological network theory and methodology. *Perspect Psychol Sci* 2017; **12**: 999–1020.

Supporting information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

Appendix S1. Exploring the links between specific depression symptoms and brain structure: A network study.

Figure S1. Centrality.

Figure S2. Stability.

Eva Hilland, PhD ^{1,2}, Nils I. Landrø, PhD,^{1,2} Brage Kraft, PhD,² Christian K. Tamnes, PhD,^{1,3,4} Eiko I. Fried, PhD,⁵ Luigi A. Maglanoc, PhD^{2,3} and Rune Jonassen, PhD⁶

¹Department of Psychiatry, Diakonhjemmet Hospital, ²Clinical Neuroscience Research Group, Department of Psychology, ³NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, ⁴PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway, ⁵Clinical Psychology Unit, Institute of Psychology, University of Leiden, Leiden, The Netherlands, and ⁶Department of Nursing and Health Promotion, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway

Email: eva.hilland@psykologi.uio.no

Received 22 August 2019; revised 5 December 2019;

accepted 9 December 2019.

Effectiveness of topiramate for polydipsia with clozapine-ineffective, treatment-resistant schizophrenia

doi:10.1111/pcn.12973

Approximately 20% of schizophrenic patients have associated polydipsia,¹ and they account for 80% of polydipsia patients. Once polydipsia proceeds to water intoxication, increased impulsivity often brings them seclusion and prolonged hospitalization. Schizophrenic patients are reported to have a shortened lifespan, and it is even shorter when they have comorbid polydipsia.² Medications for polydipsia have not been identified but are urgently needed to promote deinstitutionalization and an improved life prognosis. We found only one report on topiramate,³ and additional verification is necessary. We describe a case in which topiramate was effective for polydipsia of treatment-resistant schizophrenia, with submission approval of an Institutional Review Board after the treatment. The patient and her sister gave us a signed release, and patient anonymity has been secured.

A 57-year-old woman was hospitalized for the 25th time because of delusions, auditory hallucinations, and violent behaviors. She was diagnosed with schizophrenia and mild mental retardation (full-scale IQ of 61 on the